Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2019-06-14 Board/Management Inform…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). This document specifically details changes to the company's board of directors, which falls under the category of Board/Management Information.
2019-06-14 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for the company 'Genome & Company'. It details the resolutions passed, including the appointment of directors and the approval of stock options. This falls under the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it reports the outcome of shareholder voting at a general meeting.
2019-06-14 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting periods, submitted to the Financial Services Commission/Korea Exchange. This type of disclosure regarding share-based compensation and capital structure changes falls under the 'Regulatory Filings' category as it is a specific corporate disclosure requirement that does not fit into the other specialized categories like DIRS (insider trading) or SHA (share issuance).
2019-06-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) for Genome & Company. It contains the meeting agenda, details on director appointments, stock option grants, and management reference materials (business overview, market analysis). This type of document is standard for proxy solicitation and shareholder meeting materials, which falls under the 'Proxy Solicitation & Information Statement' category.
2019-05-30 Korean
기타주요경영사항(자율공시)(상환전환우선주의 보통주 전환)
Share Issue/Capital Change Classification · 98% confidence The document is a regulatory filing from Genome & Company regarding the conversion of Redeemable Convertible Preferred Shares (RCPS) into common stock. This involves a change in the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues, stock splits, or other capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2019-05-22 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a shareholder meeting (주주총회소집 결의) issued by Genome & Company. It outlines the date, location, and specific agenda items (such as the appointment of an outside director and the granting of stock options) to be voted upon by shareholders. This type of document is a standard proxy solicitation material used to inform shareholders of upcoming meeting details and agenda items, fitting the definition of Proxy Solicitation & Information Statement.
2019-05-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.